Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global estimates of mortality in newborn babies, children, and adolescents.

BMJ (Clinical research ed.)·2026
Same author

Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.

Blood·2026
Same author

Optimization of a parallel CAR for B-cell lymphoma via ITAM attenuation and target specificity validation.

Clinical and experimental immunology·2026
Same author

Predicting Salmonella Typhi incidence using prevalence metrics from sentinel studies of community-onset bloodstream infections: a secondary analysis of observational data.

Vaccine·2026
Same author

Correction: Leveraging paired serology to estimate the incidence of typhoidal Salmonella infection in the STRATAA study.

PLoS neglected tropical diseases·2026
Same author

Comparison of Cadaveric Warming Rates in Accidental Hypothermia Between Continuous and Dwell Thoracic Lavage.

The Journal of emergency medicine·2026
Same journal

Erythrocytapheresis Improves Health-Related Quality of Life in High-Altitude Migrants with Chronic Mountain Sickness: A Single-Arm Before-After Trial at 4,000-4,500 m.

High altitude medicine & biology·2026
Same journal

Health Promotion for Sun Protection: A Community Approach in a Mountain Setting.

High altitude medicine & biology·2026
Same journal

<i>Letter:</i> The Experience of Health Care Providers Working At High Altitude.

High altitude medicine & biology·2026
Same journal

<i>Letter:</i> Beyond Altitude-Referral Filters and Diagnostic Gaps in Young Stroke.

High altitude medicine & biology·2026
Same journal

Mitigating Intraoperative Fatigue in Surgeons at High Altitude: A Stepped-Wedge Cluster Randomized Trial.

High altitude medicine & biology·2026
Same journal

Exercise-Induced Autonomic and Cardio-Respiratory Stress at High Altitude in Leisure Athletes.

High altitude medicine & biology·2026
See all related articles

Related Experiment Videos

Acetazolamide fails to decrease pulmonary artery pressure at high altitude in partially acclimatized humans.

Buddha Basnyat1, Jenny Hargrove, Peter S Holck

  • 1Nepal International Clinic, Kathmandu, Nepal., Himalayan Rescue Association, Kathmandu, Nepal.

High Altitude Medicine & Biology
|September 20, 2008
PubMed
Summary
This summary is machine-generated.

Acetazolamide did not prevent high altitude pulmonary edema (HAPE) in trekkers. However, it significantly reduced acute mountain sickness incidence, suggesting a minor role in HAPE prevention due to acclimatization.

Related Experiment Videos

Area of Science:

  • Altitude Medicine
  • Cardiopulmonary Physiology
  • Pharmacology

Background:

  • High altitude pulmonary edema (HAPE) is a life-threatening condition.
  • Acetazolamide is commonly used for altitude sickness prevention.
  • Its efficacy in preventing HAPE requires further investigation.

Purpose of the Study:

  • To evaluate acetazolamide's effectiveness in preventing HAPE among trekkers.
  • To assess acetazolamide's impact on pulmonary artery systolic pressures (PASP) at high altitude.
  • To explore the association between PASP and HAPE symptoms.

Main Methods:

  • Randomized, double-blind, placebo-controlled trial.
  • Participants trekked to altitudes up to 5000m in Nepal.
  • HAPE diagnosed using Lake Louise Criteria; PASP measured via cardiac ultrasonography.

Main Results:

  • No HAPE cases observed in either acetazolamide or placebo groups.
  • No significant difference in mean PASP between groups.
  • Acetazolamide significantly reduced acute mountain sickness (10.2% vs 21.9%).
  • Increased HAPE signs/symptoms correlated with elevated PASP (p < 0.01).

Conclusions:

  • Study inconclusive on acetazolamide's HAPE prevention efficacy due to zero HAPE cases.
  • Acetazolamide effectively reduces acute mountain sickness.
  • Lack of PASP effect suggests acetazolamide's HAPE prevention role may be minor, potentially due to pre-existing acclimatization.